–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks. –If approved, TrenibotE will be the first neurotoxin of its kind available to patients.–Submission is supported by data from over 2,100 patients treated with TrenibotE throughout the clinical program. NORTH CHICAGO, Ill., April 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submis ...

Market Overview - US stock index futures are all down, with Dow futures down 0.47%, S&P 500 futures down 0.31%, and Nasdaq futures down 0.26% [1] - European indices also show declines, with Germany's DAX down 0.07%, UK's FTSE 100 down 0.04%, France's CAC40 down 0.14%, and the Euro Stoxx 50 down 0.18% [2] - WTI crude oil increased by 1.25% to $63.05 per barrel, while Brent crude rose by 1.03% to $66.80 per barrel [2] US Stock Market Insights - Jefferies highlights a critical point for the S&P 500 index at 5500, which needs to be breached to recover from a 19% drop since February's historical high [3] - Christopher Wood from Jefferies suggests that the golden era for US stocks is over, predicting further declines in US equities, bonds, and the dollar [5] Automotive Industry - Japanese automakers saw a surge in US sales in March, with Toyota's sales up 8% to 231,336 units, Honda's up 13%, and Nissan's up 10% [4] Company Earnings Reports - Merck's Q1 earnings exceeded expectations with sales of $15.5 billion, although they anticipate a $200 million loss due to tariffs by 2025 [9] - American Airlines withdrew its 2025 profit guidance, reporting a Q1 net loss of $473 million, worsened by tariff pressures and government spending uncertainties [9] - Procter & Gamble lowered its annual organic sales growth forecast from 3%-5% to 2% due to tariff pressures and fluctuating consumer demand [10] - Sanofi's Q1 earnings surpassed expectations, driven by strong demand for its Dupixent drug, with sales of €9.89 billion [10] - IBM reported Q1 sales of $14.5 billion, exceeding expectations, but concerns remain regarding the impact of tariffs and government spending cuts on business [11] - Texas Instruments provided a positive Q2 earnings outlook, with expected revenue between $4.17 billion and $4.53 billion, driven by improved demand in industrial and automotive sectors [12] Technology Sector - Google Chrome's potential market value is estimated at over $50 billion, according to competitors, amid ongoing antitrust scrutiny [13] - TSMC plans to begin production using A14 chip technology in 2028, aiming to maintain its leadership in the semiconductor industry [13]

ALLEGATIONS: According to the complaint, Cerevel's October 16, 2023 secondary stock offering (the "October Offering" or "Offering") documents and other public statements omitted material facts regarding AbbVie's interest in acquiring Cerevel at a price well in excess of the $22.81 per share Offering price, artificially deflating Cerevel's stock price until the merger was announced. Moreover, Cerevel's controlling shareholder, Bain Capital Investors, LLC ("Bain"), acquired Cerevel shares from the October Off ...

Due to the essentiality of healthcare, the medical sector can provide a defensive hedge against market uncertainty, and investors may be eyeing AbbVie (ABBV)  and HCA Healthcare (HCA)  stock ahead of their Q1 reports on Friday, April 25.Being the largest non-governmental operator of acute care hospitals in the United States, HCA shares are up a very respectable +11% year to date, with pharmaceutical giant AbbVie’s stock virtually flat but outperforming the benchmark S&P 500’s 10% decline as well. That said, ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][4] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [3]. - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [5]. Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [4]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [4]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [6].

Core Viewpoint - AbbVie is expected to report first-quarter 2025 earnings on April 25, with sales estimated at $12.91 billion and earnings at $2.40 per share, although earnings estimates have declined recently [1][6]. Financial Performance - AbbVie has a history of exceeding earnings expectations, with a trailing four-quarter average earnings surprise of 2.37% and a recent surprise of 1.41% [1]. - The company anticipates adjusted earnings between $2.34 and $2.38 per share and net revenues of approximately $12.8 billion for the upcoming quarter [6]. Revenue Drivers - Sales growth is expected to be driven by newer immunology drugs, Skyrizi and Rinvoq, with consensus estimates for their sales at $3.19 billion and $1.61 billion, respectively [7]. - The immunology franchise is projected to generate $6.1 billion in revenues, including $3.2 billion from Skyrizi, $1.6 billion from Rinvoq, and $900 million from U.S. Humira [9]. Challenges - AbbVie has faced sales erosion following the loss of patent protection for Humira, with consensus estimates for its sales at $1.32 billion [8]. - The oncology segment is expected to generate $1.5 billion, with Imbruvica sales declining due to competition, estimated at $676 million [10]. Neuroscience and Aesthetics Segments - Neuroscience sales are projected at $2.1 billion, driven by products like Botox Therapeutic and Vraylar, with consensus estimates at $2.16 billion [13]. - Aesthetics sales are expected to be impacted by sluggish growth in Botox and Juvederm, with estimates at $1.14 billion [14]. Stock Performance and Valuation - AbbVie shares have declined 2% year-to-date, outperforming the industry and S&P 500 [16]. - The stock trades at a price/earnings ratio of 13.58, slightly below the industry average of 14.89, but above its five-year mean of 12.06 [19]. Long-term Outlook - AbbVie is well-positioned for growth despite challenges, with strong sales from Skyrizi and Rinvoq, and a proactive approach to pipeline development [21][22]. - The company has entered the obesity treatment market, indicating strategic expansion [23]. - Despite some declining estimates, the solid pipeline and growth prospects for 2025 sales and profits suggest a reason to remain invested in AbbVie stock [24].

Core Viewpoint - Analysts project AbbVie (ABBV) will report quarterly earnings of $2.40 per share, a 3.9% increase year over year, with revenues expected to reach $12.91 billion, reflecting a 4.8% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.8% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Revenue- Botox Cosmetic- Total' at $576.62 million, down 8.9% year over year [5]. - 'Net Revenue- Imbruvica' is projected to be $676.15 million, reflecting a decrease of 19.3% from the prior-year quarter [5]. - 'Net Revenue- Eye Care- Total' is expected to be $531.41 million, indicating a slight decline of 1.2% [5]. - 'Net Revenue- Juvederm Collection- Total' is forecasted at $253.59 million, down 14.6% from the year-ago quarter [6]. - 'Net Revenue- Creon- US' is estimated at $267.00 million, a decrease of 6.3% year over year [6]. - 'Net Revenue- Rinvoq- International' is projected to reach $504.96 million, an increase of 37.2% from the prior-year quarter [6]. - 'Net Revenue- Rinvoq- US' is expected to be $1.09 billion, reflecting a significant increase of 50.2% year over year [7]. - 'Net Revenue- Humira- International' is estimated at $422.30 million, down 15.4% from the prior-year quarter [7]. - 'Net Revenue- Humira- US' is projected at $898.84 million, indicating a substantial decline of 49.3% year over year [7]. - 'Net Revenue- Immunology- Skyrizi- International' is expected to be $507.22 million, up 44.1% year over year [8]. - 'Net Revenue- Immunology- Skyrizi- US' is projected at $2.69 billion, reflecting a 62.3% increase year over year [8]. - The consensus estimate for 'Geographic Revenues- International' stands at $3.42 billion, indicating a 4.5% increase from the prior-year quarter [9]. Stock Performance - Over the past month, AbbVie shares have returned -18.7%, compared to the Zacks S&P 500 composite's -8.9% change [9].

Core Insights - The Medical sector's first-quarter 2025 earnings season is gaining momentum, with strong initial results from Johnson & Johnson, which exceeded earnings and sales estimates and raised its sales guidance for the year [1] - As of April 16, 3.3% of Medical sector companies reported earnings, with 100% surpassing earnings estimates and 50% exceeding revenue estimates, indicating a positive trend for the sector [1] - Overall, first-quarter earnings for the Medical sector are projected to increase by 34.7%, while sales are expected to rise by 7.5% compared to the previous year [1] Gilead Sciences - Gilead Sciences has a strong earnings track record, beating estimates in the last four quarters with an average surprise of 19.47% [3] - For Q1 2025, Gilead has an Earnings ESP of +3.07% and a Zacks Rank of 3, with consensus earnings estimated at $1.73 per share [5] - The company's revenue is expected to be supported by its HIV therapies, although it may face challenges due to the new Medicare Part D model affecting discounts [6][7] Bristol Myers - Bristol Myers has also shown a solid earnings performance, beating estimates in the last four quarters with an average surprise of 16.18% [8] - For the upcoming quarter, Bristol Myers has an Earnings ESP of -0.51% and a Zacks Rank of 3, with consensus earnings estimated at $1.54 per share [8] - Revenue is anticipated to be impacted by declining sales from legacy drugs, but this may be offset by growth in newer products [9] Merck - Merck has a favorable earnings history, beating estimates in the last four quarters with an average surprise of 4.68% [11] - For Q1 2025, Merck has an Earnings ESP of -2.04% and a Zacks Rank of 3, with consensus earnings estimated at $2.16 per share [11] - Revenue growth is expected to be driven by the strong performance of its cancer drug Keytruda, although international sales of the HPV vaccine Gardasil may be negatively affected [12] AbbVie - AbbVie has consistently beaten earnings estimates, with an average surprise of 2.37% over the last four quarters [13] - For the upcoming quarter, AbbVie has an Earnings ESP of -3.61% and a Zacks Rank of 3, with consensus earnings estimated at $2.47 per share [13] - The company's revenue is likely to be bolstered by strong sales of key drugs and contributions from newer products [14] Sanofi - Sanofi has a mixed earnings record, beating estimates in two of the last four quarters, with an average surprise of 5.14% [15] - For Q1 2025, Sanofi has an Earnings ESP of +1.62% and a Zacks Rank of 3, with consensus earnings estimated at 90 cents per share [15] - Revenue is expected to benefit from higher sales of Dupixent and new products, although lower flu vaccine sales and generic competition may pose challenges [16]

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded c ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-tra ...